Proxygen Announces Strategic Collaboration with Merck to Develop Molecular Glue Degraders
09-Jun-2022 -
Proxygen announced that the company has entered into a strategic multi-year research collaboration and license agreement with Merck. Proxygen is eligible to receive up to€495 million ($554 million at the average USD/EUR FX rate of Q1 2022)in continuous R&D funding, upfront and success-based ...
funding
license agreements
Merck